MersV1, PubMed, Corpus, bibRecord, 000972

Addressing the selectivity and toxicity of antiviral nucleosides.

Identifieur interne : 000972 ( PubMed/Corpus ); précédent : 000971; suivant : 000973

Addressing the selectivity and toxicity of antiviral nucleosides.

Auteurs : Joy Y. Feng

Source :

Antiviral chemistry & chemotherapy [ 2040-2066 ]

RBID : pubmed:29534607

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (toxicity), Humans, Molecular Structure, Nucleosides (pharmacology), Nucleosides (toxicity), Toxicity Tests, Viruses (drug effects).
MESH :
- chemical , pharmacology : Antiviral Agents, Nucleosides.
- chemical , toxicity : Antiviral Agents, Nucleosides.
- drug effects : Viruses.
- Animals, Humans, Molecular Structure, Toxicity Tests.

Abstract

Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and are valued for their impressive potency and high barrier to resistance. They have been approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other emerging viruses. However, this class of compounds has also experienced a high attrition rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and cell-based assays and provide recommendations for assessing toxicity liability before entering animal toxicity studies.

DOI: 10.1177/2040206618758524
PubMed: 29534607

Links to Exploration step

pubmed:29534607

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Addressing the selectivity and toxicity of antiviral nucleosides.</title>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation><nlm:affiliation>2158 Gilead Sciences Inc. , Foster City, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2018 Jan-Dec</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:29534607</idno>
<idno type="pmid">29534607</idno>
<idno type="doi">10.1177/2040206618758524</idno>
<idno type="wicri:Area/PubMed/Corpus">000972</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000972</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Addressing the selectivity and toxicity of antiviral nucleosides.</title>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation><nlm:affiliation>2158 Gilead Sciences Inc. , Foster City, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral chemistry & chemotherapy</title>
<idno type="eISSN">2040-2066</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (toxicity)</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Nucleosides (pharmacology)</term>
<term>Nucleosides (toxicity)</term>
<term>Toxicity Tests</term>
<term>Viruses (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Nucleosides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiviral Agents</term>
<term>Nucleosides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Viruses</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Toxicity Tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and are valued for their impressive potency and high barrier to resistance. They have been approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other emerging viruses. However, this class of compounds has also experienced a high attrition rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and cell-based assays and provide recommendations for assessing toxicity liability before entering animal toxicity studies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29534607</PMID>
<DateCompleted><Year>2019</Year>
<Month>06</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>06</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2040-2066</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>26</Volume>
<PubDate><MedlineDate>2018 Jan-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Antiviral chemistry & chemotherapy</Title>
<ISOAbbreviation>Antivir. Chem. Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Addressing the selectivity and toxicity of antiviral nucleosides.</ArticleTitle>
<Pagination><MedlinePgn>2040206618758524</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/2040206618758524</ELocationID>
<Abstract><AbstractText>Nucleoside and nucleotide analogs have played significant roles in antiviral therapies and are valued for their impressive potency and high barrier to resistance. They have been approved for treatment of herpes simplex virus-1, HIV, HBV, HCV, and influenza, and new drugs are being developed for the treatment of RSV, Ebola, coronavirus MERS, and other emerging viruses. However, this class of compounds has also experienced a high attrition rate in clinical trials due to toxicity. In this review, we discuss the utility of different biochemical and cell-based assays and provide recommendations for assessing toxicity liability before entering animal toxicity studies.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Joy Y</ForeName>
<Initials>JY</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-4837-1911</Identifier>
<AffiliationInfo><Affiliation>2158 Gilead Sciences Inc. , Foster City, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Antivir Chem Chemother</MedlineTA>
<NlmUniqueID>9009212</NlmUniqueID>
<ISSNLinking>0956-3202</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009705">Nucleosides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009705" MajorTopicYN="N">Nucleosides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018675" MajorTopicYN="Y">Toxicity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nucleosides</Keyword>
<Keyword MajorTopicYN="N">antiviral therapy</Keyword>
<Keyword MajorTopicYN="N">chain termination</Keyword>
<Keyword MajorTopicYN="N">nucleotides</Keyword>
<Keyword MajorTopicYN="N">polymerase</Keyword>
<Keyword MajorTopicYN="N">prodrugs</Keyword>
<Keyword MajorTopicYN="N">selectivity</Keyword>
<Keyword MajorTopicYN="N">virus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>3</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>3</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>6</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29534607</ArticleId>
<ArticleId IdType="doi">10.1177/2040206618758524</ArticleId>
<ArticleId IdType="pmc">PMC5890540</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Toxicol Pathol. 1999 Nov-Dec;27(6):607-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10588540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2006 Jan-Feb;16(1):37-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16287208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2013 Oct 15;272(2):272-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23811329</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Sci. 2007 May;97(1):205-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17150972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1995 Oct 26;333(17):1099-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7565947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Investig Drugs. 2009 Jun;18(6):709-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19426125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Pharmacol Toxicol. 2011;51:1-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20809796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2014 Apr 15;11(4):e1001628</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2007 Sep;12(17-18):777-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17826691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Drug Metab Toxicol. 2014 Aug;10 (8):1061-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25023361</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2001 Nov 2;276(44):40847-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11526116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2016 Nov 21;60(12 ):7077-7085</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27645237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1991 Mar 2;337(8740):508-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1671889</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1996 Apr 25;334(17):1135; author reply 1137-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8598879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Pharmacol. 1991 May;39(5):625-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1851960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Sci. 2016 Oct;153(2):396-408</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27466212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Sci. 2007 Jun;97(2):539-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17361016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Bioenerg Biomembr. 2012 Aug;44(4):421-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22689143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2000 Feb 22;39(7):1702-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10677218</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lab Invest. 1997 Jan;76(1):77-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9010451</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2015 Nov 23;60(2):806-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26596942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 2010 Sep 1;404(1):75-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20465991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2012;8(11):e1003030</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23166498</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2002 Mar;46(3):716-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11850253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1992 Sep;36(9):2061-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1329643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Liver Dis. 2014 Feb;34(1):37-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24782257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2017 Jul;143:151-161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28412183</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1992 Feb 15;267(5):2856-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1310674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aliment Pharmacol Ther. 2016 Mar;43(6):674-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26787287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014;58(4):1930-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24419349</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 2006 Jul 14;72(2):239-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16720018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol In Vitro. 2013 Mar;27(2):560-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23147640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Death. 2017 Feb 24;10 :1179670717691251</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28469473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1980 Nov;18(5):741-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7192534</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Infect Dis. 2000 Feb;13(1):5-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11964766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19918064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2002 Jul;3(7):415-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12142171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Drug Saf. 2009 Jan;4(1):34-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19149524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>In Vitro Cell Dev Biol. 1989 Apr;25(4):321-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2654122</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000972 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000972 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:29534607
   |texte=   Addressing the selectivity and toxicity of antiviral nucleosides.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:29534607" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Addressing the selectivity and toxicity of antiviral nucleosides.

Addressing the selectivity and toxicity of antiviral nucleosides.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki